Golidocitinib — Investigational Agent
Other · Phase 2 · Dizal Pharmaceutical
Mechanism of Action
Oral highly selective JAK1 inhibitor that suppresses JAK1-STAT signaling driving proliferation and survival of malignant T cells, exploiting JAK/STAT pathway dependence in peripheral T-cell lymphomas.
Investigational Indications
- Relapsed/refractory peripheral T-cell lymphoma
- Newly diagnosed peripheral T-cell lymphoma (combination)